HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors
Hangzhou-based HighField Biopharmaceutical, a specialist in immuno-oncology biotech focused on targeted lipid-based therapies, has revealed...
HighField Biopharmaceutical
HighField Biopharmaceutical Doses First Patient in HFK1 Clinical Trial Targeting Solid Tumors
Hangzhou-based HighField Biopharmaceutical, a leader in immuno-oncology focused on innovative lipid-based therapies, has announced the...
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...